EU calls for a return to full dosing of Genzyme's Fabrazyme

10/24/2010 | Reuters

The European Medicines Agency has recommended that doctors resume prescribing the full dose of Genzyme's Fabry disease drug Fabrazyme after the agency found a steady increase in adverse events among patients receiving a lower dose. Dosing of the treatment was reduced last year because of a supply shortage prompted by issues at Genzyme's manufacturing facility.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care